This research used single-cell RNA sequencing to examine bone marrow cell populations in osteogenesis imperfecta (OI) and healthy bone, aiming to identify microenvironmental features that may influence OI phenotype beyond collagen gene mutations. The authors report that transcriptional profiling at single-cell resolution revealed altered proportions of mesenchymal and immune cell subpopulations and changes in osteogenic gene expression in OI samples compared with controls.
Bone specimens were obtained from surgical procedures. The analysis included two healthy individuals and three OI patients. The three OI cases comprised two patients with type-I OI carrying a mutation in COL1A1 and one patient with type-VIII OI associated with LEPRE1 mutations, which affect the 3-hydroxylation of type I collagen. Ethical approval was provided by the Biobank Research Ethics Committee of the University Medical Center Utrecht (biobank number 18-685; tissue release protocol number 26-041). The authors state that informed consent and relevant institutional approvals were obtained.
Bone-derived cells were isolated and subjected to single-cell RNA sequencing. The dataset underwent quality control and bioinformatics processing, including clustering and differential gene expression analyses. Clustering delineated distinct mesenchymal and immune cell subpopulations in the bone samples. Specific pipelines, parameters, and code locations were not detailed in the source beyond the statement that quality control and bioinformatics analysis were performed.
Comparative analysis revealed that all OI samples had a reduced proportion of mesenchymal stromal cells (MSCs) relative to healthy controls. The study highlights that these microenvironmental changes exist in addition to primary collagen defects and may contribute to disease variability. Immune cell subpopulations were also identified as distinct clusters, although the source focuses primarily on mesenchymal and bone-turnover cell differences.
The single-cell data showed different patterns between OI subtypes:
In OI type I (COL1A1 mutation), authors observed a decrease in osteoblast numbers accompanied by an increase in osteoclast precursor cells. This pattern suggests diminished osteogenic cell presence together with enhanced resorption potential, which could exacerbate bone fragility.
In OI type VIII (LEPRE1 mutation), cells associated with bone turnover—osteoblasts, osteoclast precursors, and osteoclasts—were all elevated. This indicates a distinct remodeling milieu in type VIII compared to type I, with concurrent increases in formation- and resorption-related cells.
These subtype-specific differences emphasize that alterations in the bone marrow microenvironment may be shaped by underlying genetic defects and vary between OI forms.
Across both OI types studied, mesenchymal stromal cells exhibited downregulation of osteogenic regulators, specifically BMP5 and RUNX1. The reduction in expression of these genes within MSCs aligns with the observed decrease in osteoblast numbers in type I and suggests impaired osteogenic differentiation potential of MSCs in OI generally. The source reports these gene-expression changes but does not provide additional mechanistic experiments or functional validation within this preprint.
The findings indicate that OI pathology extends beyond collagen structural defects to include significant alterations in the bone marrow microenvironment. Reduced MSC proportions and downregulated osteogenic gene expression point to impaired osteogenic differentiation. Furthermore, the contrasting cellular patterns between type I and type VIII OI suggest that microenvironmental remodeling is patient- and genotype-specific, potentially contributing to the wide phenotypic variability observed even among individuals with the same collagen mutation.
The authors conclude that these microenvironmental disturbances—reduced MSCs, altered osteoblast and osteoclast populations, and downregulation of BMP5 and RUNX1—are likely important contributors to OI bone pathology. The source does not report therapeutic implications or interventions based on these findings; it focuses on descriptive single-cell transcriptomic differences.
The authors state that all data produced in the study are available on reasonable request and that, upon peer-reviewed publication, data will be posted online. Funding was declared from the China Scholarship Council. The authors reported no competing interests. Ethics approvals and participant consent were confirmed as described above.
Note on limitations
The source reports a small cohort (two healthy controls and three OI patients) and heterogeneity between OI subtypes. Additional limitations or detailed statistical metrics were not provided in the source document. Further validation in larger, more diverse cohorts and functional follow-up studies would be required to confirm and extend these observations.